Sign Out
Thromboreductin is indicated for the reduction of elevated platelet counts and associated clinical symptoms in at high risk essential thrombocythemia patients.
An at high risk essential thrombocythaemia patient is defined by one or more of the following features: Age ≥60 years; Platelet count ≥1.000 x 109/l; A history of thrombo-haemorrhagic events.
Continue with Google